Zobrazeno 1 - 10
of 45
pro vyhledávání: '"Forment, JV"'
Autor:
Asim, M, Tarish, F, Zecchini, HI, Sanjiv, K, Gelali, E, Massie, CE, Baridi, A, Warren, AY, Zhao, W, Ogris, C, McDuffus, L-A, Mascalchi, P, Shaw, G, Dev, H, Wadhwa, K, Wijnhoven, P, Forment, JV, Lyons, SR, Lynch, AG, O'Neill, C, Zecchini, VR, Rennie, PS, Baniahmad, A, Tavaré, S, Mills, IG, Galanty, Y, Crosetto, N, Schultz, N, Neal, D, Helleday, T
Publikováno v:
Nature Communications, Vol 8, Iss 1, Pp 1-10 (2017)
Nature Communications
Asim, M, Tarish, F, Ireland-Zecchini, H, Sanjiv, K, Gelali, E, Massie, C E, Baridi, A, Warren, A Y, Zhao, W, Ogris, C, McDuffus, L-A, Mascalchi, P, Shaw, G L, Dev, H, Wadhwa, K, Wijnhoven, P, Forment, J V, Lyons, S R, Lynch, A G, O'Neill, C, Zecchini, V R, Rennie, P S, Baniahmad, A, Tavaré, S, Mills, I G, Galanty, Y, Crosetto, N, Schultz, N, Neal, D E & Helleday, T 2017, ' Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer ', Nature Communications, vol. 8, no. 1, pp. 374 . https://doi.org/10.1038/s41467-017-00393-y
Nature Communications
Asim, M, Tarish, F, Ireland-Zecchini, H, Sanjiv, K, Gelali, E, Massie, C E, Baridi, A, Warren, A Y, Zhao, W, Ogris, C, McDuffus, L-A, Mascalchi, P, Shaw, G L, Dev, H, Wadhwa, K, Wijnhoven, P, Forment, J V, Lyons, S R, Lynch, A G, O'Neill, C, Zecchini, V R, Rennie, P S, Baniahmad, A, Tavaré, S, Mills, I G, Galanty, Y, Crosetto, N, Schultz, N, Neal, D E & Helleday, T 2017, ' Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer ', Nature Communications, vol. 8, no. 1, pp. 374 . https://doi.org/10.1038/s41467-017-00393-y
Emerging data demonstrate homologous recombination (HR) defects in castration-resistant prostate cancers, rendering these tumours sensitive to PARP inhibition. Here we demonstrate a direct requirement for the androgen receptor (AR) to maintain HR gen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::c2bd153c3c2b27cda275d2deb5d68ea4
http://ora.ox.ac.uk/objects/uuid:
http://ora.ox.ac.uk/objects/uuid:
Autor:
Forment, JV, Herzog, M, Coates, J, Konopka, T, Gapp, BV, Nijman, SM, Adams, DJ, Keane, TM, Jackson, SP
In model organisms, classical genetic screening via random mutagenesis provides key insights into the molecular bases of genetic interactions, helping to define synthetic lethality, synthetic viability and drug-resistance mechanisms. The limited gene
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______109::f78eba11b64a7a3c88d2e52de11af5c7
https://www.repository.cam.ac.uk/handle/1810/260961
https://www.repository.cam.ac.uk/handle/1810/260961
Autor:
Rodriguez R, Miller KM, Forment JV, Bradshaw CR, Nikan M, Britton S, Oelschlaegel T, Xhemalce B, Balasubramanian S, Jackson SP
Publikováno v:
Nature Chemical Biology.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=erc_________::c603c3b8183c8d53c37bbdc8eb6e036f
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Forment, JV, Herzog, M, Coates, J, Konopka, T, Gapp, BV, Nijman, SM, Adams, DJ, Keane, TM, Jackson, SP
In model organisms, classical genetic screening via random mutagenesis provides key insights into the molecular bases of genetic interactions, helping to define synthetic lethality, synthetic viability and drug-resistance mechanisms. The limited gene
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5adc6b758ca6424b5ba809f9317c8d8a
Autor:
Voulgarelis D; AstraZeneca Postdoc Programme, Cambridge, UK.; DMPK Oncology R&D, AstraZeneca, Cambridge, UK.; Oncology Data Science, Oncology R&D, AstraZeneca, Cambridge, UK., Forment JV; Bioscience, Oncology R&D, AstraZeneca, Cambridge, UK., Herencia Ropero A; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain., Polychronopoulos D; Oncology Data Science, Oncology R&D, AstraZeneca, Cambridge, UK., Cohen-Setton J; Oncology Data Science, Oncology R&D, AstraZeneca, Cambridge, UK., Bender A; Clinical Pharmacology & Safety Sciences, AstraZeneca, Cambridge, UK.; Centre for Molecular Informatics, Department of Chemistry, University of Cambridge, Cambridge, UK., Serra V; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain., O'Connor MJ; Bioscience, Oncology R&D, AstraZeneca, Cambridge, UK. mark.j.oconnor@astrazeneca.com., Yates JWT; DMPK Modelling, DMPK, Preclinical Sciences, RTech, GSK, Stevenage, UK., Bulusu KC; Oncology Data Science, Oncology R&D, AstraZeneca, Cambridge, UK. krishna.bulusu@astrazeneca.com.
Publikováno v:
NPJ precision oncology [NPJ Precis Oncol] 2024 Nov 18; Vol. 8 (1), pp. 266. Date of Electronic Publication: 2024 Nov 18.
Autor:
Coelho MA; Translational Cancer Genomics, Wellcome Sanger Institute, Hinxton, UK. matthew.coelho@sanger.ac.uk.; Cancer Genome Editing, Wellcome Sanger Institute, Hinxton, UK. matthew.coelho@sanger.ac.uk.; Open Targets, Cambridge, UK. matthew.coelho@sanger.ac.uk., Strauss ME; EMBL-European Bioinformatics Institute, Cambridge, UK.; Cancer Research UK, Cambridge Institute, University of Cambridge, Cambridge, UK.; Gene Editing and Cellular Research and Development, Wellcome Sanger Institute, Hinxton, UK.; Department of Mathematics and Statistics, University of Exeter, Exeter, UK., Watterson A; Translational Cancer Genomics, Wellcome Sanger Institute, Hinxton, UK., Cooper S; Gene Editing and Cellular Research and Development, Wellcome Sanger Institute, Hinxton, UK., Bhosle S; Translational Cancer Genomics, Wellcome Sanger Institute, Hinxton, UK., Illuzzi G; Bioscience, Oncology R&D, AstraZeneca, Cambridge, UK., Karakoc E; Translational Cancer Genomics, Wellcome Sanger Institute, Hinxton, UK.; Open Targets, Cambridge, UK., Dinçer C; Translational Cancer Genomics, Wellcome Sanger Institute, Hinxton, UK., Vieira SF; Translational Cancer Genomics, Wellcome Sanger Institute, Hinxton, UK.; Open Targets, Cambridge, UK., Sharma M; Translational Cancer Genomics, Wellcome Sanger Institute, Hinxton, UK., Moullet M; Translational Cancer Genomics, Wellcome Sanger Institute, Hinxton, UK., Conticelli D; Department of Oncology, University of Turin, Turin, Italy.; Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy., Koeppel J; Generative and Synthetic Genomics, Wellcome Sanger Institute, Hinxton, UK., McCarten K; Translational Cancer Genomics, Wellcome Sanger Institute, Hinxton, UK., Cattaneo CM; Department of Immunology and Molecular Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands.; Experimental Hematology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy., Veninga V; Department of Immunology and Molecular Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands.; Department of Pathology, Stanford University, Stanford, CA, USA., Picco G; Translational Cancer Genomics, Wellcome Sanger Institute, Hinxton, UK.; Open Targets, Cambridge, UK., Parts L; Generative and Synthetic Genomics, Wellcome Sanger Institute, Hinxton, UK., Forment JV; Bioscience, Oncology R&D, AstraZeneca, Cambridge, UK., Voest EE; Department of Immunology and Molecular Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands., Marioni JC; EMBL-European Bioinformatics Institute, Cambridge, UK.; Cancer Research UK, Cambridge Institute, University of Cambridge, Cambridge, UK.; Genentech, South San Francisco, CA, USA., Bassett A; Gene Editing and Cellular Research and Development, Wellcome Sanger Institute, Hinxton, UK., Garnett MJ; Translational Cancer Genomics, Wellcome Sanger Institute, Hinxton, UK. mathew.garnett@sanger.ac.uk.; Open Targets, Cambridge, UK. mathew.garnett@sanger.ac.uk.
Publikováno v:
Nature genetics [Nat Genet] 2024 Nov; Vol. 56 (11), pp. 2479-2492. Date of Electronic Publication: 2024 Oct 18.
Autor:
Herencia-Ropero A; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Carrer Natzaret 115-117, 08035, Barcelona, Spain.; Department of Biochemistry and Molecular Biology, Autonomous University of Barcelona, Barcelona, Spain., Llop-Guevara A; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Carrer Natzaret 115-117, 08035, Barcelona, Spain. alballop@gmail.com., Staniszewska AD; Oncology R&D, AstraZeneca, Cambridge, UK., Domènech-Vivó J; Hereditary Cancer Genetics Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Carrer Natzaret 115-117, 08035, Barcelona, Spain.; Programa de doctorat en Biomedicina, Universitat de Barcelona, Barcelona, Spain., García-Galea E; Oncology Data Science Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Moles-Fernández A; Medicine Genetics Group, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.; Department of Clinical and Molecular Genetics, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Pedretti F; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Carrer Natzaret 115-117, 08035, Barcelona, Spain., Domènech H; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Carrer Natzaret 115-117, 08035, Barcelona, Spain., Rodríguez O; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Carrer Natzaret 115-117, 08035, Barcelona, Spain., Guzmán M; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Carrer Natzaret 115-117, 08035, Barcelona, Spain., Arenas EJ; Growth Factors Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer, Monforte de Lemos, Madrid, Spain.; Epigenetics Group, Josep Carreras Leukaemia Research Institute, Barcelona, Spain., Verdaguer H; Preclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.; Gastrointestinal and Endocrine Tumor Unit, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Calero-Nieto FJ; Oncology R&D, AstraZeneca, Cambridge, UK., Talbot S; Oncology R&D, AstraZeneca, Cambridge, UK., Tobalina L; Oncology R&D, AstraZeneca, Cambridge, UK., Leo E; Oncology R&D, AstraZeneca, Cambridge, UK., Lau A; Oncology R&D, AstraZeneca, Cambridge, UK., Nuciforo P; Molecular Oncology Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Dienstmann R; Oncology Data Science Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Macarulla T; Preclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.; Gastrointestinal and Endocrine Tumor Unit, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Arribas J; Growth Factors Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer, Monforte de Lemos, Madrid, Spain.; Departament of Medicine and Life Sciences, Pompeu Fabra University, Barcelona, Spain.; Catalan Institution for Research and Advanced Studies, ICREA, Barcelona, Spain.; Cancer Research Program, The Hospital del Mar Research Institute, Barcelona, Spain., Díez O; Hereditary Cancer Genetics Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Carrer Natzaret 115-117, 08035, Barcelona, Spain.; Department of Clinical and Molecular Genetics, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Gutiérrez-Enríquez S; Hereditary Cancer Genetics Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Carrer Natzaret 115-117, 08035, Barcelona, Spain., Forment JV; Oncology R&D, AstraZeneca, Cambridge, UK., O'Connor MJ; Oncology R&D, AstraZeneca, Cambridge, UK., Albertella M; Oncology R&D, AstraZeneca, Cambridge, UK., Balmaña J; Hereditary Cancer Genetics Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Carrer Natzaret 115-117, 08035, Barcelona, Spain. jbalmana@vhio.net.; Department of Medical Oncology, Vall d'Hebron Barcelona Hospital Campus, Autonomous University of Barcelona, Barcelona, Spain. jbalmana@vhio.net., Serra V; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Carrer Natzaret 115-117, 08035, Barcelona, Spain. vserra@vhio.net.
Publikováno v:
Genome medicine [Genome Med] 2024 Aug 26; Vol. 16 (1), pp. 107. Date of Electronic Publication: 2024 Aug 26.
Autor:
Davies N; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham., Francis T; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham., Oldreive C; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham., Azam M; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham., Wilson J; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham., Byrd PJ; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham., Burley M; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham., Sharma-Oates A; School of Biosciences, University of Birmingham, Birmingham., Keane P; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham., Alatawi S; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK; Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, University of Tabuk, Tabuk., Higgs MR; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham., Rudzki Z; Department of Histopathology, University Hospitals Birmingham NHS Foundation Trust, Birmingham., Ibrahim M; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK; South Egypt Cancer Institute, Assiut University, Egypt., Perry T; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham., Agathanggelou A; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham., Hewitt AM; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham., Smith E; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham., Bonifer C; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham., O'Connor M; Bioscience Oncology RandD, AstraZeneca, Cambridge., Forment JV; Bioscience Oncology RandD, AstraZeneca, Cambridge., Murray PG; School of Medicine, Bernal Institute, Health Research Institute and LDCRC, University of Limerick, Limerick, Ireland., Fennell E; School of Medicine, Bernal Institute, Health Research Institute and LDCRC, University of Limerick, Limerick, Ireland., Kelly G; Blood Cells and Bood Cancer Division, The Walter and Eliza Hall Institute of Medical Research, Victoria., Chang C; Blood Cells and Bood Cancer Division, The Walter and Eliza Hall Institute of Medical Research, Victoria., Stewart GS; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham., Stankovic T; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham. t.stankovic@bham.ac.uk., Kwok M; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK; Centre for Clinical Haematology, Queen Elizabeth Hospital Birmingham, Birmingham. m.kwok@bham.ac.uk., Taylor AM; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham. a.m.r.taylor@bham.ac.uk.
Publikováno v:
Haematologica [Haematologica] 2024 Jun 06. Date of Electronic Publication: 2024 Jun 06.
Autor:
Dibitetto D; Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, 3012, Bern, Switzerland. diego.dibitetto@marionegri.it.; Cancer Therapy Resistance Cluster and Bern Center for Precision Medicine, Department for Biomedical Research, University of Bern, 3012, Bern, Switzerland. diego.dibitetto@marionegri.it.; Department of Experimental Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, via Mario Negri 2, 20156, Milan, Italy. diego.dibitetto@marionegri.it., Liptay M; Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, 3012, Bern, Switzerland.; Cancer Therapy Resistance Cluster and Bern Center for Precision Medicine, Department for Biomedical Research, University of Bern, 3012, Bern, Switzerland., Vivalda F; Institute of Molecular Cancer Research, University of Zürich, Zürich, Switzerland., Dogan H; Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, 3012, Bern, Switzerland.; Cancer Therapy Resistance Cluster and Bern Center for Precision Medicine, Department for Biomedical Research, University of Bern, 3012, Bern, Switzerland., Gogola E; Division of Molecular Pathology, The Netherlands Cancer Institute, 1066CX, Amsterdam, The Netherlands.; Oncode Institute, Amsterdam, The Netherlands., González Fernández M; Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, 3012, Bern, Switzerland.; Cancer Therapy Resistance Cluster and Bern Center for Precision Medicine, Department for Biomedical Research, University of Bern, 3012, Bern, Switzerland., Duarte A; Division of Molecular Pathology, The Netherlands Cancer Institute, 1066CX, Amsterdam, The Netherlands.; Oncode Institute, Amsterdam, The Netherlands., Schmid JA; Institute of Molecular Cancer Research, University of Zürich, Zürich, Switzerland., Decollogny M; Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, 3012, Bern, Switzerland.; Cancer Therapy Resistance Cluster and Bern Center for Precision Medicine, Department for Biomedical Research, University of Bern, 3012, Bern, Switzerland., Francica P; Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, 3012, Bern, Switzerland.; Cancer Therapy Resistance Cluster and Bern Center for Precision Medicine, Department for Biomedical Research, University of Bern, 3012, Bern, Switzerland., Przetocka S; Institute of Molecular Cancer Research, University of Zürich, Zürich, Switzerland., Durant ST; DDR Biology, Bioscience, Oncology R&D, AstraZeneca, Cambridge, CB4 0WG, UK., Forment JV; DDR Biology, Bioscience, Oncology R&D, AstraZeneca, Cambridge, CB4 0WG, UK., Klebic I; Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, 3012, Bern, Switzerland., Siffert M; Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, 3012, Bern, Switzerland., de Bruijn R; Division of Molecular Pathology, The Netherlands Cancer Institute, 1066CX, Amsterdam, The Netherlands.; Oncode Institute, Amsterdam, The Netherlands., Kousholt AN; Oncode Institute, Amsterdam, The Netherlands.; Biotech Research and Innovation Centre, University of Copenhagen, 2200 N, Copenhagen, Denmark., Marti NA; Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, 3012, Bern, Switzerland.; Cancer Therapy Resistance Cluster and Bern Center for Precision Medicine, Department for Biomedical Research, University of Bern, 3012, Bern, Switzerland., Dettwiler M; Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, 3012, Bern, Switzerland., Sørensen CS; Biotech Research and Innovation Centre, University of Copenhagen, 2200 N, Copenhagen, Denmark., Tille JC; Division of Clinical Pathology, Department of Diagnostics, Hôpitaux Universitaires de Genève, Geneva, Switzerland., Undurraga M; Division of Gynecology, Department of Pediatrics and Gynecology, Hôpitaux Universitaires de Genève, Geneva, Switzerland., Labidi-Galy I; Faculty of Medicine, Department of Medicine and Center of Translational Research in Onco-Hematology, University of Geneva, Swiss Cancer Center Leman, Geneva, Switzerland.; Department of Oncology, Hôpitaux Universitaires de Genève, 4, Rue Gabrielle Perret-Gentil, Geneva, 1205, Switzerland., Lopes M; Institute of Molecular Cancer Research, University of Zürich, Zürich, Switzerland., Sartori AA; Institute of Molecular Cancer Research, University of Zürich, Zürich, Switzerland., Jonkers J; Division of Molecular Pathology, The Netherlands Cancer Institute, 1066CX, Amsterdam, The Netherlands. j.jonkers@nki.nl.; Oncode Institute, Amsterdam, The Netherlands. j.jonkers@nki.nl., Rottenberg S; Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, 3012, Bern, Switzerland. sven.rottenberg@unibe.ch.; Cancer Therapy Resistance Cluster and Bern Center for Precision Medicine, Department for Biomedical Research, University of Bern, 3012, Bern, Switzerland. sven.rottenberg@unibe.ch.; Division of Molecular Pathology, The Netherlands Cancer Institute, 1066CX, Amsterdam, The Netherlands. sven.rottenberg@unibe.ch.
Publikováno v:
Nature communications [Nat Commun] 2024 May 24; Vol. 15 (1), pp. 4430. Date of Electronic Publication: 2024 May 24.